59 citations
,
August 2021 in “Frontiers in Endocrinology” This review discusses the roles and therapeutic effects of GLP-1 receptor agonists on the nervous, cardiovascular, and endocrine systems, but reports no new clinical results, emphasizing the need for further research on their impact on metabolism and tumor relationships in type 2 diabetes patients.
3 citations
,
July 2025 in “Obesity Facts” This review examines how GLP-1 receptor agonists might impact metabolic and reproductive outcomes in polycystic ovary syndrome, but it reports no new clinical findings and highlights the need for further research.
1 citations
,
August 2026 in “Pediatric Dermatology” This review suggests that dermatologic adverse events associated with GLP-1 receptor agonists may occur more frequently in children than adults, but pediatric data remain limited and less robust compared to adult data.
1 citations
,
September 2025 in “Dermatology and Therapy” This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.
April 2026 in “Open MIND” This review article discusses the aesthetic impacts of GLP-1 medications like Ozempic (semaglutide), including "Ozempic Face," skin sagging, and loss of lean mass, and explores potential recovery methods such as biostimulators, HIFU, endolaser, and PRP.